Kathleen DeRose

Statistics

Publications

Citations

H-Index

Active since

2021

Affiliations

GlaxoSmithKline (United Kingdom)(Current)

GlaxoSmithKline (United States)

University of Occupational and Environmental Health Japan

Kathleen DeRose is an author at GlaxoSmithKline (United Kingdom) specializing in clinical pharmacology, efficacy evaluation, and treatment response monitoring.

ORCID

Publications per year

2021–2022

Publications

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea

Yoshiya Tanaka, Sang‐Cheol Bae, Damon Bass et al. · RMD Open · 2021 · 22 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

Fengchun Zhang, Jie Zheng, Yang Li et al. · RMD Open · 2022 · 17 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study

Yoshiya Tanaka, Paula Curtis, Kathleen DeRose et al. · Modern Rheumatology · 2021 · 11 citations

Medicine, Clinical Sciences, Pharmacotherapy +16

1–3 of 3